Health
Targeted therapies developed to reduce lung fibrosis – Medical Xpress
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
People with idiopathic pulmonary fibrosis (IPF) have a life expectancy of less than five years. Fibrotic diseases cause organ failure that lead to about 45% of all deaths in the United States. Existing therapies do little to slow progression.
Now, Philip S. Low, the Purdue Ralph C. Corley Distinguished Professor of Chemistry and Presidential Scholar…
-
Noosa News23 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
General22 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off
-
Noosa News23 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
General21 hours agoTruck driver charged with causing death by dangerous driving after highway crash